Budralazine

This classification denotes an antihypertensive agent with the molecular formula C14H16N4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S0177QHV2B, chemically known as 1(2h)-phthalazinone, (1,3-dimethyl-2-butenylidene)hydrazone but generally known as budralazine, which bears US NIH Compound Identifier 6419536. Budralazine most often comes in base and hydrochloride forms. European Medicines Agency schedules Budralazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05958MIG. The term BUDRALAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). BUDRALAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule budralazine under HS 29339990 and SITC 51577. As of Q4 2014, BUDRALAZINE remains the US FDA Preferred Term for this commodity. Budralazine bears US NLM identifiers UMLS ID C0054203 and NCI Concept Code C79901. SMILES: N(/N=C(/C=C(/C)C)C)c1nncc2c1cccc2.